ISO 35001:2019 - Biorisk Management for Laboratories Lead Implementer Free Practice Test — 30 Questions

Question 1

A biosafety lead implementer is tasked with developing a comprehensive biorisk management strategy for a research laboratory that has recently begun working with a novel, highly transmissible viral agent known to produce aerosols during routine experimental procedures. The laboratory operates under national biosafety regulations that mandate a risk-based approach to biological agent handling. Which of the following principles should most strongly guide the selection and prioritization of control measures for this specific scenario?

Accepted Answer

Prioritizing controls that effectively reduce the likelihood and impact of exposure to the novel viral agent, particularly concerning aerosol generation, based on a thorough risk assessment.

Question 2

A biosafety officer at a research facility is reviewing the biorisk management plan for a new project involving the manipulation of a novel, highly pathogenic avian influenza strain. During the risk assessment phase, it was determined that a specific centrifugation step, performed to isolate viral particles, poses a significant risk of aerosol generation. The laboratory has already explored options for elimination and substitution of the procedure and pathogen, which were deemed not feasible for the research objectives. Considering the principles outlined in ISO 35001:2019 for managing risks associated with highly pathogenic biological agents and aerosol-generating procedures, which engineering control would be the most appropriate and effective measure to implement for this centrifugation step to ensure the highest level of containment and minimize exposure risk?

Accepted Answer

Performing the centrifugation within a Class II biological safety cabinet.

Question 3

A research laboratory, currently operating under Biosafety Level 2 (BSL-2) protocols for its viral vector work, is planning to introduce a novel lentiviral vector system that requires Biosafety Level 3 (BSL-3) containment due to enhanced pathogenic potential and aerosolization risk. As the lead implementer for ISO 35001:2019, what is the most appropriate initial step to ensure a compliant and effective transition of the biorisk management system?

Accepted Answer

Conduct a comprehensive review and update of the laboratory's entire biorisk management system, integrating the new BSL-3 requirements for the lentiviral vector system into the existing framework.

Question 4

A research laboratory working with a BSL-2 pathogen experiences an unexpected aerosolization event during a routine centrifugation procedure, leading to potential exposure of personnel outside the primary containment device. Considering the principles of ISO 35001:2019, what is the most immediate and critical action the laboratory’s biorisk management team must undertake to address this containment breach?

Accepted Answer

Immediately activate the laboratory's emergency response plan, focusing on containment of the released agent and decontamination of affected personnel and areas.

Question 5

A research laboratory working with a novel strain of *Bacillus anthracis* (BSL-2) experiences an unexpected aerosolization event during a routine sample transfer, potentially compromising the primary containment barrier. The laboratory has a documented biorisk management system aligned with ISO 35001:2019. Which of the following actions represents the most immediate and critical response to mitigate the potential spread of the agent and ensure the safety of personnel and the environment?

Accepted Answer

Immediately activate the laboratory's documented emergency response plan for containment breaches, including securing the affected area and initiating communication protocols.

Question 6

When initiating the development of a biorisk management system compliant with ISO 35001:2019, what is the most foundational prerequisite for effectively establishing the system\'s scope and objectives?

Accepted Answer

A comprehensive assessment and characterization of the laboratory's specific biological agents, processes, and potential exposure pathways.

Question 7

When initiating the development of a comprehensive biorisk management system in a high-containment virology laboratory, what is the most critical initial step to ensure alignment with ISO 35001:2019 requirements and effective risk mitigation?

Accepted Answer

Conduct a thorough analysis of the laboratory's internal and external context, including relevant legal and regulatory frameworks, and identify key interested parties and their expectations.

Question 8

A research laboratory specializing in virology is conducting experiments with a novel, highly pathogenic avian influenza virus. During the risk assessment phase for a new experimental protocol, the team identifies a significant risk of aerosol generation and potential laboratory-acquired infection during sample preparation. Considering the principles of the hierarchy of controls as mandated by ISO 35001:2019, which of the following actions would represent the most effective and preferred risk mitigation strategy to address this identified hazard?

Accepted Answer

Investigate the feasibility of substituting the live, pathogenic virus with a well-characterized, attenuated strain or a suitable surrogate that can provide equivalent experimental data without the same level of inherent risk.

Question 9

When establishing a biorisk management system (BRMS) in a clinical diagnostic laboratory that handles novel pathogens, what is the most critical initial step in understanding the operational environment as per ISO 35001:2019 requirements, considering both internal capabilities and external regulatory landscapes?

Accepted Answer

Systematically identifying all relevant interested parties and their specific biorisk-related requirements, including national and international biosafety regulations and local public health directives.

Question 10

When a research laboratory is tasked with developing containment and handling procedures for a newly identified viral agent with unknown pathogenicity and transmission routes, what is the most critical initial step in establishing an effective biorisk management system compliant with ISO 35001:2019?

Accepted Answer

Conducting a thorough analysis of the laboratory's internal and external context, including identifying all relevant interested parties and their specific biorisk-related requirements.

Question 11

A research laboratory working with a newly isolated strain of highly pathogenic avian influenza (HPAI) discovers that the virus exhibits an unexpectedly high rate of genetic reassortment in vitro, a characteristic not fully captured in their initial biosafety risk assessment. This oversight has led to the use of containment measures and personal protective equipment (PPE) that are now deemed insufficient to mitigate the potential for aerosolized transmission during specific experimental procedures. Considering the principles outlined in ISO 35001:2019 for managing biorisks in laboratories, what is the most appropriate immediate corrective action to address this identified deficiency?

Accepted Answer

Conduct a comprehensive review and update of the risk assessment to incorporate the newly understood viral reassortment characteristics, followed by the implementation of revised, enhanced containment and PPE protocols.

Question 12

A newly established biosafety laboratory, specializing in the research of novel zoonotic pathogens, is undergoing the initial phase of implementing a biorisk management system (BRMS) aligned with ISO 35001:2019. The laboratory director has tasked the lead implementer with defining the system\'s scope. The laboratory operates under stringent national biosafety regulations, receives funding from international health organizations with specific reporting requirements, and is situated in a densely populated urban area with heightened public health awareness. Which foundational step is paramount for the lead implementer to undertake before definitively establishing the scope of the BRMS?

Accepted Answer

Thoroughly analyze the laboratory's operational context, including relevant national and international regulations, stakeholder expectations, and the specific nature of the biological agents handled.

Question 13

Following the implementation of enhanced biosafety protocols for handling a newly identified viral agent in a research laboratory, which action represents the most critical next step in adhering to the principles of ISO 35001:2019 for continuous improvement of biorisk management?

Accepted Answer

Conduct a comprehensive review of the implemented protocols, including environmental monitoring and personnel competency assessments, to validate their effectiveness in mitigating identified risks.

Question 14

When assessing a laboratory\'s adherence to ISO 35001:2019, what specific action by top management most effectively demonstrates their commitment to integrating the biorisk management system into the laboratory\'s overall strategic direction and operational processes?

Accepted Answer

Ensuring the biorisk management system's policies and objectives are incorporated into the laboratory's strategic planning and daily operational procedures.

Question 15

When a newly established biosafety laboratory is undergoing its initial implementation phase for ISO 35001:2019, which foundational element is paramount for ensuring the systematic and effective integration of biorisk management principles across all operational levels and functions?

Accepted Answer

The clear definition and communication of organizational roles, responsibilities, and authorities for biorisk management activities.

Question 16

A newly established biosafety laboratory, aiming for ISO 35001:2019 compliance, is developing its foundational biorisk management system (BRMS). The laboratory director is seeking the most effective strategy to ensure the BRMS is not merely a set of documented procedures but a living, integrated system that actively mitigates potential hazards. Considering the standard\'s emphasis on a systematic and proactive approach, which of the following strategies would best achieve this objective?

Accepted Answer

Embedding the biorisk assessment and control cycle into routine operational procedures and decision-making processes at all levels.

Question 17

A high-containment laboratory in a developing nation is initiating research on a newly identified zoonotic pathogen with potential for rapid airborne transmission. The laboratory director, a lead implementer for biorisk management, must establish the foundational understanding of the organization and its context as per ISO 35001:2019. Which of the following best encapsulates the critical external and internal factors that must be systematically identified and analyzed to effectively establish the laboratory\'s biorisk management system in this specific scenario?

Accepted Answer

National biosafety regulations, international agreements on pathogen handling, the laboratory's existing safety culture, and the specific containment capabilities of its facilities.

Question 18

A newly appointed lead implementer for biorisk management at a high-containment virology laboratory is tasked with ensuring robust top management commitment and the seamless integration of the ISO 35001:2019 standard into the laboratory\'s existing operational framework. Considering the foundational requirements of the standard, which strategic action by the lead implementer would most effectively establish this crucial alignment and support from the outset?

Accepted Answer

Facilitate a comprehensive review of the laboratory's operational context and stakeholder expectations to inform the BRMS scope and objectives, ensuring alignment with strategic goals.

Question 19

A research laboratory, operating under ISO 35001:2019, begins working with a novel strain of influenza virus that preliminary genomic sequencing suggests possesses enhanced transmissibility and potential for aerosolization compared to previously handled strains. This necessitates a reclassification of the work to a higher biosafety level (BSL-3) than initially planned. Which of the following actions is the most appropriate immediate response to ensure continued compliance and effective biorisk management?

Accepted Answer

Initiate a comprehensive review of the existing biorisk assessment, update control measures for the new BSL-3 requirements, and implement necessary procedural and facility modifications.

Question 20

A biosafety level 3 laboratory, specializing in emerging infectious diseases, has completed a comprehensive biorisk assessment for a newly acquired, highly pathogenic avian influenza strain. The assessment identified several critical risks related to aerosol generation during sample processing and potential breaches in primary containment. The team has proposed a suite of control measures, including enhanced negative pressure ventilation, mandatory use of specialized personal protective equipment (PPE) with integrated respiratory protection, and the development of detailed standard operating procedures (SOPs) for all manipulation steps. Considering the principles of ISO 35001:2019, what is the most logical and critical next step in the biorisk management process following the identification and proposed implementation of these controls?

Accepted Answer

Implement the identified control measures and establish a robust monitoring program to verify their effectiveness and ensure ongoing compliance.

Question 21

A research laboratory specializing in virology has recently synthesized a novel, attenuated strain of influenza virus intended for vaccine development. During a routine internal audit, a potential breach in the primary containment barrier of a biosafety cabinet (BSC) was identified during a specific manipulation involving aerosol generation. The audit team suspects that the current operational procedures and the BSC\'s maintenance schedule may not adequately address the specific risk profile of this genetically modified agent. Considering the principles outlined in ISO 35001:2019 for managing biorisks in laboratories, what is the most prudent immediate course of action for the laboratory\'s biorisk management committee?

Accepted Answer

Conduct a detailed risk assessment of the identified containment breach, evaluate the effectiveness of existing controls, and implement enhanced containment measures or procedural modifications to mitigate the risk.

Question 22

A research laboratory working with a Biosafety Level 2 (BSL-2) pathogen experiences an incident where a researcher inadvertently exits the primary containment area without completing the required decontamination procedures for their personal protective equipment, leading to a potential secondary exposure pathway. The laboratory\'s risk assessment had previously identified procedural lapses as a low-probability, high-consequence risk. Which of the following corrective actions, aligned with the principles of ISO 35001:2019, would most effectively address the root cause of this containment breach?

Accepted Answer

Implementing enhanced supervisory oversight and mandatory refresher training on decontamination protocols for all laboratory personnel, coupled with a system for periodic procedural audits.

Question 23

A research laboratory working with a genetically modified BSL-2 organism, known for its increased virulence, experienced a near-miss when a centrifuge tube fractured during operation, potentially compromising containment. The laboratory\'s biorisk management system, designed according to ISO 35001:2019 principles, requires a systematic response. Considering the incident\'s potential to expose personnel and the environment, what is the most critical immediate step the biorisk lead should undertake to address this breach in the established control framework?

Accepted Answer

Initiate a thorough investigation to identify root causes and implement corrective and preventive actions.

Question 24

A newly established virology laboratory in a region experiencing an increase in arboviral disease outbreaks is tasked with implementing ISO 35001:2019. The laboratory\'s primary focus is on research involving Dengue virus serotypes and potential vector control strategies. Considering the requirements of Clause 4.1, \"Understanding the organization and its context,\" which of the following actions would most effectively establish the foundational understanding necessary for a robust biorisk management system?

Accepted Answer

Conducting a comprehensive review of relevant national and international biosafety regulations, public health advisories pertaining to arboviral diseases, and the laboratory's specific research objectives and capabilities.

Question 25

A biosafety laboratory, following the principles of ISO 35001:2019, has meticulously documented its hazard identification and risk analysis for all high-containment procedures. The laboratory has also formally evaluated these risks against its defined acceptance criteria, concluding that several identified risks necessitate mitigation. However, the laboratory has not yet implemented or documented the specific engineering controls, administrative procedures, or personal protective equipment required to address these unacceptable risks. Based on the lifecycle of biorisk management as defined by the standard, which stage of the process remains significantly incomplete?

Accepted Answer

Risk treatment

Question 26

A laboratory working with a BSL-2 agent experiences an unexpected loss of containment during a routine procedure, resulting in a small, localized spill within a designated biosafety cabinet. The incident was immediately contained by the trained personnel present. According to the principles of ISO 35001:2019, what is the most critical subsequent action to be taken by the laboratory\'s biorisk management team to ensure effective response and prevent recurrence?

Accepted Answer

Conduct a comprehensive root cause analysis of the containment loss and implement corrective and preventive actions based on the findings.

Question 27

A research laboratory in a densely populated urban area is preparing to work with a newly isolated viral agent exhibiting characteristics of rapid airborne transmission and significant pathogenicity. The laboratory has previously operated under Biosafety Level 2 (BSL-2) protocols. Considering the principles of ISO 35001:2019 for biorisk management, what is the most critical initial step to ensure the safe introduction and handling of this agent, aligning with regulatory expectations and best practices?

Accepted Answer

Conduct a comprehensive, documented risk assessment to determine the appropriate biosafety level and necessary control measures, informing the development of specific standard operating procedures.

Question 28

When initiating the development of a comprehensive biorisk management system (BRMS) in a high-containment research facility, what is the most foundational and critical first step to ensure alignment with ISO 35001:2019 principles?

Accepted Answer

Defining the scope and context of the BRMS, including identifying relevant internal and external issues and interested parties.

Question 29

When establishing a comprehensive biorisk management system in a clinical diagnostics laboratory operating under ISO 35001:2019, which critical initial step ensures that the subsequent identification of hazards and assessment of risks are grounded in the laboratory\'s operational reality and strategic objectives?

Accepted Answer

Thoroughly defining the laboratory's operational context, encompassing both internal and external factors that could influence its biorisk management efforts.

Question 30

A research laboratory, currently operating under Biosafety Level 2 (BSL-2) protocols for handling a novel viral agent, receives approval to escalate its containment procedures to Biosafety Level 3 (BSL-3) due to new findings regarding the agent\'s transmissibility and pathogenicity. As the Lead Implementer for the biorisk management system (BRMS), what is the most critical initial step to ensure the laboratory\'s compliance with ISO 35001:2019 during this transition?

Accepted Answer

Conduct a comprehensive risk assessment for all activities involving the viral agent at BSL-3, identifying new or modified control measures required for facility design, personal protective equipment, and waste disposal.

ISO 35001:2019 - Biorisk Management for Laboratories Lead Implementer Free Practice Test — 30 Questions

A lot more is already mapped out

About the ISO 35001:2019 - Biorisk Management for Laboratories Lead Implementer Certification